 |
|
|
|
 |
|
|
Article 1 - 5 of 6 of the company Frost & Sullivan |
|
Outsourcing to India and China: Cultural diffculties with the perception of costs
Frost & Sullivan interview with Mr. Steve Fishwick, AstraZeneca
Aparna Singh (AS), Program Manager for the Chemicals Materials and Foods team at Frost & Sullivan India, recently caught up with Mr. Steve Fishwick (SF), Projects Group Director, AstraZeneca at the Frost & Sullivan's Global Life Sciences Summit 2006 at Goa, India. He was one of the key speakers at this premium summit....
|
|
Wyeth 'learns and confirms' in India
Frost & Sullivan interview with Dr. Michael Kolb, Wyeth
Aparna Singh (AS), Program Manager with Frost & Sullivan's Chemical Materials and Foods team caught up with Dr. Michael Kolb (Dr. MK) at Frost & Sullivan's Opportunities in Lifescience Molecules: Global Partnership Summit 2006. This annual summit was held at Goa (India) from 21st -23rd May, 2006....
|
|
Frost & Sullivan's Global PharmAlliance 2005: Becoming the Partner of Choice
Looking at the increasing trend towards partnerships and alliances in the pharmaceutical industry, Frost & Sullivan a global growth consulting company had organized a premium conference, "Global PharmAlliance 2005 - Becoming the partner of choice" in Mumbai (India). The two day event focused on giving an insight into the world of partnerships and alliances through......
|
|
Outsourcing in Pharmaceutical Industry
Pharmaceutical industry is constantly undergoing a change. In the past pharmaceuticals had a different strategy, companies use to build all the products internally and confine access to information or resources to third parties. The past situation is changing; in-house resources are getting exhausted with a very thin product pipeline and in addition many drugs are going off patent by 2008 hampering company sales and competitiveness. It takes $800 million and 20 years for......
|
|
Outsourcing in Clinical Research - The Indian Perspective
New pharmaceutical strategies pursue increased Research and Development (R&D) investments ranging 15-20% in contrast to late 80's period where classical model across was 10%. The annual budget allocation spent with clinical research organizations (CRO) is approximately $12 billion in an attempt to increase throughput, which has predominantly benefited CRO's who have seen their turnover boost growth of 20-30% year on year....
|
|
|
Additional information
Frost & Sullivan
London, United Kingdom
Company
News
|
|
|
|
|
|
Top
